Previous Article | Next Article ![]()
Infect. Immun., 01 1998, 59-64, Vol 66, No. 1
MM Gozar, VL Price and DC Kaslow
Transmission-blocking vaccines based on sexual-stage surface antigens of
Plasmodium falciparum may assist in the control of this lethal form of
human malaria. Two vaccine candidates, Pfs25 and Pfs28, were produced as
single recombinant fusion proteins. The 39-kDa chimeric proteins, having a
C-terminal His6 tag, were secreted by Saccharomyces cerevisiae, using the
prepro-alpha-factor leader sequence. Pfs25-28 fusion proteins were
significantly more potent than either Pfs25 or Pfs28 alone in eliciting
antibodies in mice that blocked oocyst development in Anopheles freeborni
mosquitoes: complete inhibition of oocyst development in the mosquito
midgut was achieved with fewer vaccinations, at a lower dose, and for a
longer duration than with either Pfs25 or Pfs28 alone. Increased
antigen-specific immunoglobulin G titers and highly significant
lymphoproliferative stimulation by Pfs28-containing antigens suggest the
presence of an immunodominant helper T-cell epitope in the Pfs28 portion of
the fusion proteins. This epitope may be responsible for the enhanced
humoral response to both Pfs25 and Pfs28 antigens. Protein production of
the fusion protein was improved 12-fold by converting Pfs28 codons to
yeast-preferred codons (TBV28), using a modified ADH2 promoter and
incorporating a (Glu-Ala)2 repeat after the Kex2 cleavage site.
Copyright © 1998, American Society for Microbiology
Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice
Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892-0425, USA.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|